【24h】

Dose reduction in molecular breast imaging

机译:减少乳腺分子影像的剂量

获取原文

摘要

Molecular Breast Imaging (MBI) is the imaging of radiolabeled drugs, cells, or nanoparticles for breast cancer detection, diagnosis, and treatment. Screening of broad populations of women for breast cancer with mammography has been augmented by the emergence of breast MRI in screening of women at high risk for breast cancer. Screening MBI may benefit the sub-population of women with dense breast tissue that obscures small tumors in mammography. Dedicated breast imaging equipment is necessary to enable detection of early-stage tumors less than 1 cm in size. Recent progress in the development of these instruments is reviewed. Pixellated CZT for single photon MBI imaging of ~(99m)Tc-sestamibi gives high detection sensitivity for early-stage tumors. The use of registered collimators in a near-field geometry gives significantly higher detection efficiency - a factor of 3.6 -, which translates into an equivalent dose reduction factor given the same acquisition time. The radiation dose in the current MBI procedure has been reduced to the level of a four-view digital mammography study. In addition to screening of selected sub-populations, reduced MBI dose allows for dual-isotope, treatment planning, and repeated therapy assessment studies in the era of molecular medicine guided by quantitative molecular imaging.
机译:分子乳腺癌成像(MBI)是用于乳腺癌检测,诊断和治疗的放射性标记药物,细胞或纳米颗粒的成像。乳房MRI的出现增加了通过乳房X线摄影对广泛女性乳腺癌的筛查,从而筛查了罹患乳腺癌的高风险女性。筛查MBI可能有益于乳腺X线摄影中掩盖小肿瘤的乳腺组织密集的女性亚人群。专用乳房成像设备对于检测小于1厘米大小的早期肿瘤是必不可少的。综述了这些仪器开发的最新进展。用于〜(99m)Tc-司他他比的单光子MBI成像的像素化CZT对早期肿瘤具有很高的检测灵敏度。在近场几何结构中使用配准准直器可以显着提高检测效率(系数为3.6),在相同的采集时间下,这可以转化为等效的剂量降低系数。当前MBI程序中的辐射剂量已降低到四视图数字化乳腺X线照片研究的水平。除了筛选选定的亚群外,减少的MBI剂量还允许在定量分子成像指导下的分子医学时代进行双同位素,治疗计划和重复治疗评估研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号